Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    BioMarin Pharmaceutical I...

    NASDAQ: BMRN · Real-Time Price · USD
    55.28
    -0.83 (-1.48%)
    At close: Jun 05, 2025, 3:59 PM
    55.49
    0.38%
    After-hours: Jun 05, 2025, 07:48 PM EDT

    BioMarin Pharmaceutical Statistics

    Share Statistics

    BioMarin Pharmaceutical has 191.78M shares outstanding. The number of shares has increased by 0.47% in one year.

    Shares Outstanding

    n/a
    		 191.78M

    Shares Change (YoY)

    n/a
    		 0.47%

    Shares Change (QoQ)

    n/a
    		 0.1%

    Owned by Institutions (%)

    n/a
    		 96.19%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 35

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 4.45M, so 2.33% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 4.45M

    Short % of Shares Out

    n/a
    		 2.33%

    Short % of Float

    n/a
    		 2.35%

    Short Ratio (days to cover)

    n/a
    		 2.62

    Valuation Ratios

    The PE ratio is 29.26 and the forward PE ratio is 13.42. BioMarin Pharmaceutical's PEG ratio is 0.21.

    PE Ratio

    n/a
    		 29.26

    Forward PE

    n/a
    		 13.42

    PS Ratio

    n/a
    		 4.38

    Forward PS

    n/a
    		 2.6

    PB Ratio

    n/a
    		 2.21

    P/FCF Ratio

    n/a
    		 26.27

    PEG Ratio

    n/a
    		 0.21
    Financial Ratio History

    Enterprise Valuation

    BioMarin Pharmaceutical has an Enterprise Value (EV) of 12.15B.

    EV / Sales

    n/a
    		 4.26

    EV / EBITDA

    n/a
    		 18.67

    EV / EBIT

    n/a
    		 21.21

    EV / FCF

    n/a
    		 25.56

    Financial Position

    The company has a current ratio of 5.33, with a Debt / Equity ratio of 0.11.

    Current Ratio

    n/a
    		 5.33

    Quick Ratio

    n/a
    		 3.29

    Debt / Equity

    n/a
    		 0.11

    Debt / EBITDA

    n/a
    		 0.93

    Debt / FCF

    n/a
    		 1.27

    Interest Coverage

    n/a
    		 38.23

    Financial Efficiency

    Return on Equity is 7.54% and Return on Invested Capital is 5.98%.

    Return on Equity

    n/a
    		 7.54%

    Return on Assets

    n/a
    		 6.11%

    Return on Invested Capital

    n/a
    		 5.98%

    Revenue Per Employee

    n/a
    		 $938,787.83

    Profits Per Employee

    n/a
    		 $140,414.14

    Employee Count

    n/a
    		 3,040

    Asset Turnover

    n/a
    		 0.41

    Inventory Turnover

    n/a
    		 0.47

    Taxes

    Income Tax

    n/a
    		 114.9M

    Effective Tax Rate

    n/a
    		 21.21%

    Stock Price Statistics

    The stock price has increased by -29.47% in the last 52 weeks. The beta is 0.18, so BioMarin Pharmaceutical's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.18

    52-Week Price Change

    n/a
    		 -29.47%

    50-Day Moving Average

    n/a
    		 61.27

    200-Day Moving Average

    n/a
    		 67.89

    Relative Strength Index (RSI)

    n/a
    		 34.42

    Average Volume (20 Days)

    n/a
    		 1,917,187

    Income Statement

    In the last 12 months, BioMarin Pharmaceutical had revenue of 2.85B and earned 426.86M in profits. Earnings per share was 2.13.

    Revenue

    n/a
    		 2.85B

    Gross Profit

    n/a
    		 2.27B

    Operating Income

    n/a
    		 484.21M

    Net Income

    n/a
    		 426.86M

    EBITDA

    n/a
    		 650.86M

    EBIT

    n/a
    		 554.1M

    Earnings Per Share (EPS)

    n/a
    		 2.13
    Full Income Statement

    Balance Sheet

    The company has 942.84M in cash and 602.71M in debt, giving a net cash position of 340.13M.

    Cash & Cash Equivalents

    n/a
    		 942.84M

    Total Debt

    n/a
    		 602.71M

    Net Cash

    n/a
    		 340.13M

    Retained Earnings

    n/a
    		 -194.69M

    Total Assets

    n/a
    		 7.15B

    Working Capital

    n/a
    		 2.84B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 572.84M and capital expenditures -97.42M, giving a free cash flow of 475.42M.

    Operating Cash Flow

    n/a
    		 572.84M

    Capital Expenditures

    n/a
    		 -97.42M

    Free Cash Flow

    n/a
    		 475.42M

    FCF Per Share

    n/a
    		 2.5
    Full Cash Flow Statement

    Margins

    Gross margin is 79.67%, with operating and profit margins of 16.97% and 14.96%.

    Gross Margin

    n/a
    		 79.67%

    Operating Margin

    n/a
    		 16.97%

    Pretax Margin

    n/a
    		 18.98%

    Profit Margin

    n/a
    		 14.96%

    EBITDA Margin

    n/a
    		 22.81%

    EBIT Margin

    n/a
    		 16.97%

    FCF Margin

    n/a
    		 16.66%

    Dividends & Yields

    BMRN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 3.42%

    FCF Yield

    n/a
    		 3.81%
    Dividend Details

    Analyst Forecast

    The average price target for BMRN is $90, which is 60.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $90

    Price Target Difference

    n/a
    		 60.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 22
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 $10.65

    Lynch Upside

    n/a
    		 -81.05%

    Graham Number

    n/a
    		 38.79

    Graham Upside

    n/a
    		 -30.97%

    Scores

    Altman Z-Score

    n/a
    		 6.14

    Piotroski F-Score

    n/a
    		 7

    Add to Watchlist